Latest News & Features
Big Pharma
AstraZeneca, GSK and Teva among manufacturers accused of “improper” submission of patents | More than 300 patents targeted in second wave of challenges by Federal Trade Commission | ‘Junk patents’ block competition and ramp up prices unfairly, says FTC chair. 2 May 2024
Biotechnology
Ahead of her panel discussion at LSPN North America, BioNTech’s patent counsel, shares insights into her role and ensuring innovations meet the criteria of novelty and nonobviousness. 2 May 2024
Careers
Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades. 2 May 2024
Biotechnology
Settlement comes after Acuitas alleged CureVac deliberately omitted its scientists as inventors on four US patents related to COVID-19 vaccines, claiming co-inventorship | Patents in suit relate to ongoing litigation with Pfizer and BioNTech. 30 April 2024
Biotechnology
Agreement clears the way for Sandoz to launch denosumab biosimilars in May 2025 | Dispute over multiple patents covering Prolia and Xgeva resolved. 30 April 2024
Americas
New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech. 26 April 2024
Big Pharma
GSK subsidiary and Exavir Therapeutics end dispute over licensing rights for HIV-drug compounds | Resolution follows allegations that Exavir's actions disrupted ViiV Healthcare's research collaboration with a US university. 25 April 2024
Biotechnology
Improving patient access is a UN goal but for companies transitioning from trials to full-scale production, IP is essential, explains Katherine Collins of Mewburn Ellis. 25 April 2024
Biotechnology
UK High Court invalidates two patents due to “overwhelming evidence” supplied by defendant | Biotech firm files same claims in Netherlands division of UPC on same day. 25 April 2024
Biotechnology
Vanda denied opportunity to revive patents for its sleep-disorder drug in dispute against Teva | Decision also rejects revisiting the 2007 case, KSR International v Teleflex, concerning the issue of obviousness in patent claims. 23 April 2024